- AU$1.85bn
- AU$1.40bn
- AU$39.68m
Brief: PYC Therapeutics Appoints Chief Financial Officer
Australia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director
Brief: PYC Therapeutics Requests Trading Halt
Brief: PYC Therapeutics Appoints Alan Tribe As Managing Director
Brief: PYC Therapeutics Logs FY Prelim Income From Ordinary Activities A$26.17 Mln
Australia's PYC Therapeutics soars on safety approval for its kidney disease drug trial
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$12.7 Million
Brief: PYC Therapeutics Announces Equity Raising To Raise Up To A$146 Million
Brief: PYC Therapeutics Seeks Trading Halt
Australia's PYC Therapeutics climbs to 1-month high on approval for human trials
Brief: PYC Therapeutics Says U.S. FDA Grants Rare Pediatric Disease Designation To VP-001
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says FDA Granted RPD Designation To Drug Development Program
Australia's PYC Therapeutics rises on successful neurodevelopmental drug test
Brief: PYC Therapeutics Says US FDA Grants Orphan Drug Designation To PYC Drug Candidate